On June 6, the website of the Health Planning Commission showed that the “Guiding Opinions on Promoting Family Doctors' Contracting Services†formulated by the seven ministries and commissions was officially issued. The opinion is that the family doctor contract service will be piloted this year, and strive to achieve full coverage by 2020. The opinion also pointed out that it is necessary to build a regional medical and health information platform, realize information sharing such as health records and electronic medical records, strengthen technical exchanges through telemedicine, etc., and actively use mobile Internet and wearable devices to provide various medical services for contracted residents. Promoting the signing service of family doctors is conducive to the formation of grading medical treatment and medical treatment mode, which is of great significance for improving the utilization efficiency of medical resources and alleviating the difficulty of seeing a doctor and expensive medical treatment. In this process, medical information technology is expected to play an important role. You can pay attention to Weining Health, Jiu'an Medical, and Yuyue Medical. [Public stock research report] Medical Informatization 6 Concept Share Value Analysis Weining Health: High performance continues to grow, introducing life and control fees to accelerate Category: Company Research Institute: GF Securities Co., Ltd. Researcher: Liu Xuefeng Date: 2016-04-25 2016Q1 revenue and profit maintained high growth. Benefiting from the continued prosperity of the medical information industry and the expansion of consolidated scope, the company achieved revenue of 134 million in the first quarter of 2016, a year-on-year increase of 39%, net profit of 22.15 million, a year-on-year increase of 30%, and non-net profit increased by 37%. The company's management fees and sales expenses increased rapidly due to factors such as increased personnel costs, operating capital investment, and mergers and acquisitions, which increased by 55% and 57% respectively. During the reporting period, the company sent 3 shares for every 10 shares to all shareholders and distributed a cash dividend of RMB 0.8 (including tax), and also increased one share for every 10 shares to all shareholders by capital reserve. The issuance of innovative business is abundant, and traditional business orders are guaranteed. The company's 820 million fundraising was completed, and the “4+1†strategy was solved at the fund level, and the innovative business continued to advance. Newly signed more than one million medical informatization contracts, including Datong Coal Mine Group Co., Ltd. General Hospital, Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital, Zhangjiagang City Health Planning Commission, Xiamen Renai Medical Foundation, Shanghai Shenkang Hospital Development Center, Shanghai The First People's Hospital Branch, the Second People's Hospital of Anhui Province, the Liqun Hospital of Putuo District of Shanghai, the Health Information Center of Nanjing, and the Health and Family Planning Commission of Anhui Province provide a strong guarantee for the growth of traditional businesses. 　 Cooperation with commercial insurance has risen to the capital level, and industry growth has improved the company's future space. Weining Technology, the company's original holding subsidiary, introduced strategic investor China Life. As a leading company in domestic commercial health insurance, China Life's health insurance business in 2014 and 2015 was 33.2 billion and 42 billion respectively, with a market share of 21% and 17% respectively. In the future market competition, the combination of Weining + Life can combine the advantages of both sides in technology and market coverage to achieve a certain first-mover advantage. The commercial health insurance industry is currently experiencing a small growth rate (15 years revenue 241 billion, up 52% ​​year-on-year), and the growth and ceiling of the medical insurance control industry will continue to break through. The profitability attributes of the commercial insurance company make it more rigid for the control fee. Considering the impact of diluting and Weining Technology Exchange on the company's consolidated net profit of 267 million in 2016 (not considering the consolidation of Weining Health's 16-year net profit of 202 million, a year-on-year increase of 33%), it is expected that 16-18 years of EPS They were 0.58 yuan, 0.36 yuan, and 0.53 yuan respectively, maintaining a "buy" rating. risk warning There is uncertainty in the promotion and landing progress of commercial insurance control fees; the profit model of remote health management cooperation business is still unclear and still needs long-term investment. Wanda Information: Three medical linkages are invested heavily, and the layout is showing initial results Category: Company Research Institute: China Galaxy Securities Co., Ltd. Researcher: Shen Haibing Date: 2016-04-26 Event The company disclosed the 2015 annual report on the evening of April 25, and the net profit attributable to the owner of the parent company in 2015 was 231 million yuan, an increase of 21.53% over the same period of the previous year; the operating income was 1.869 billion yuan, an increase of 21.11% over the same period of the previous year; Basic earnings per share was 0.2319 yuan, an increase of 18.92% over the same period of the previous year. The company released the first quarter performance report on the evening of April 25. During the reporting period, the net profit attributable to the owner of the parent company was 4,676,400 yuan, an increase of 25.64% over the same period of the previous year; the operating income was 292 million yuan, an increase over the same period of the previous year. 24.67%; basic earnings per share was 0.005 yuan, an increase of 25.00% over the same period of the previous year. 2. Our analysis and judgment (I), revenues grew steadily, and software and operations grew faster. In 2015, the company achieved operating income of 1.869 billion yuan, an increase of 21.11%. In the first quarter of 2016, the company achieved operating income of 292 million yuan, an increase of 24.67%. The steady growth of revenue was mainly due to the steady development of the original business, the resumption of acquisitions, and the contribution of Jintang. From the perspective of income structure, the software development and operation services revenue growth rate is high, and the integration business is basically stable. We believe that the company's revenue structure is continuously optimized, and the rapid growth of operational services indicates that the company's strategic transformation has achieved initial results. (2) The cost is large, and the huge amount of research and development is invested in the health care field. In 2015, the company's sales and management expenses increased by 41.5% and 77.5% respectively. In the first quarter of 2016, the company's sales and management expenses also increased by 28.6% and 50.7% respectively. The rapid increase in costs is mainly due to business expansion and increased scope of consolidation. The company's R&D investment has grown significantly, reaching 343 million in 15 years, up 243% year-on-year. The main growth comes from the investment of health cloud and medical cloud. We believe that the initial investment in Internet medical care and large health layout is a normal phenomenon. The ecology has been improved and gradually realized, and it is expected to receive substantial returns in the long run. (3) The layout of the three medical linkages has been continuously deepened, and the road to realization has been opened. In the past 14 years, the company has continuously improved the linkage of three medical treatments, and the current layout has been perfected. The company has successively acquired Shanghai Fugao, Ningbo Jintang, the Zhejiang Medical Insurance Control Project, the Shanghai Pharmaceutical Recruitment Platform, the Shanghai Health Cloud Project, the establishment of a full-service health entity clinic, and the construction of a Shanghai medical insurance fee platform. Based on the three-medical linkage, the basic company has cut into the healthy old-age business and formed a good synergy with the company's medical business. Wanda's grassroots community has a wide distribution and rich medical resources, which can provide better support for the elderly. The company cooperated with Taishang Lao Investment to jointly establish a pension service company to provide an innovative pension service model for China's aged care service. This cooperation also marks Wanda Information's entry into the 4 trillion pension market. The advantages of data and card position are obvious, and the road to realization is realized. Medical Cloud has already served a large number of patients in a certain province in the central region, forming a stable business flow and will expand to other regions in the future. In the medical cloud, online purchase of prescription drugs for chronic diseases has been carried out in the central city of the first-tier cities in the eastern coastal areas. The health service cloud and the cooperation with commercial insurance will also bring performance contribution to the company in the future. (4) Continuously enriching people's livelihood services, combining online and offline to enhance competitiveness In the past 16 years, the company will continue to leverage the merger and acquisition utility, carry out the core business of the industry's basic information system, and enrich the content of people's livelihood services. Focusing on Internet online services, connecting citizens and services, the online operation model is the focus. At the same time, the establishment of offline physical service benchmarks, online and offline combination to better realize. 3. Investment advice The company's performance has grown steadily. The "Medical + Medical Insurance + Medicine + O2O Health" layout is perfect. Shanghai's regional layout has deep barriers. It has cooperated with Shanghai Pharmaceutical Co., Ltd. to cut into drugs, and cooperated with Taibao to cut into the old-age field and began the process of realizing the company's value. The company's EPS for 2016-2018 is expected to be 0.31, 0.43 and 0.56 yuan respectively, maintaining the “Recommended†rating. 4. Risk warning Advance lower than expected, policy risks. Dingmin Pharmaceutical supply Pazopanib API and Pazopanib Intermediates with high purity and best price. The main products CAS No are as follows: 635702-64-6, 635702-60-2, 6973-09-7. Sample can be sent if you request.COA will be along with the quote. Tech pack can be offered. Cas 635702-64-6,Pazopanib Intermediates,Pazopanib Hcl Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com
Welcome to do business with us. Please email to us directly.